# InventisBio (Shanghai) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inventisbio-shanghai-co

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.inventisbio.com
- Total disclosed funding: $247M
- Latest round: Series D (Sep 28, 2020)
- Investors on record: 13

## About

Founded in 2015 and based in Shanghai, China, InventisBio (Shanghai) Co., Ltd. is a biopharmaceutical company that focuses on the development of drugs for tumors and metabolic diseases. In 2022, the company was listed on the Shanghai Stock Exchange. Its stock code is 688382. Yaolin Wang is the co-founder, chairman and general manager of the company.

The company's main products include oncology drug D-0502, D-1553 and metabolic disease drug D-0120, etc. D-1553 is used in non-small cell lung cancer and colorectal cancer.

## Funding rounds

- Series D, Sep 28, 2020, $147M — OrbiMed Advisors, Qiming Venture Partners, Lilly Asia Ventures, Yuecai Zhongyin Private Equity, Janchor Partners, CMB International Asset Management, Advantech Capital, MPC, DYEE Capital, Pudong Innotek, AIHC Capital, GL Ventures
- Series C, Mar 11, 2019, $70M — OrbiMed Advisors, Lilly Asia Ventures, CMB International Asset Management, Advantech Capital, Pudong Innotek
- Series B, Jun 30, 2017, $19M — OrbiMed Advisors, Lilly Asia Ventures
- Series A, May 1, 2016, $11M — Lilly Asia Ventures, Shanghai Jianyi Private Equity Fund Management

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B, Series C, Series D
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C, Series D
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series C, Series D
- Advantech Capital (https://capitalatlas.ai/funds/advantech-capital) — Series C, Series D
- Pudong Innotek — Series C, Series D
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series D
- Yuecai Zhongyin Private Equity (https://capitalatlas.ai/funds/yuecai-zhongyin-private-equity) — Series D
- Janchor Partners — Series D
- MPC — Series D
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series D
- AIHC Capital — Series D
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series D